UPDATED May 07, 2024
All the companies in the healthcare sector, including healthcare provider and equipment, healthcare tech, pharmaceuticals, biotech and life sciences.
Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | Industry | ||
---|---|---|---|---|---|---|---|---|---|---|---|
LLY | US$775.00 | -0.2% | 77.8% | US$700.3b | US$848.35 | PE113.7x | E27.0% | 0.7% | Pharmaceuticals & Biotech | ||
UNH | US$503.21 | 3.9% | 2.7% | US$460.9b | US$567.36 | PE30.1x | E19.6% | 1.5% | Healthcare | ||
JNJ | US$148.95 | -1.5% | -7.9% | US$357.9b | US$173.26 | PE21x | E6.6% | 3.3% | Pharmaceuticals & Biotech | ||
MRK | US$129.55 | 0.6% | 9.9% | US$330.2b | US$141.64 | PE142.3x | E24.9% | 2.4% | Pharmaceuticals & Biotech | ||
ABBV | US$160.45 | -0.8% | 9.6% | US$287.0b | US$181.55 | PE47.6x | E23.0% | 3.9% | Pharmaceuticals & Biotech | ||
AZN | UK£121.18 | -0.4% | 2.5% | UK£187.9b | UK£133.27 | PE37.1x | E15.9% | 2.0% | Pharmaceuticals & Biotech | ||
TMO | US$573.64 | -0.2% | 7.5% | US$218.7b | US$625.47 | PE36.3x | E10.6% | 0.3% | Pharmaceuticals & Biotech | ||
ABT | US$104.94 | -1.3% | -5.2% | US$184.7b | US$126.14 | PE32.6x | E11.3% | 2.1% | Healthcare | ||
DHR | US$249.55 | 1.1% | 6.9% | US$184.3b | US$272.68 | PE45.4x | E13.5% | 0.4% | Pharmaceuticals & Biotech | ||
AMGN | US$307.31 | 10.8% | 31.3% | US$161.1b | US$313.31 | PE43.8x | E17.8% | 2.9% | Pharmaceuticals & Biotech | ||
PFE | US$28.27 | 4.0% | -26.2% | US$157.2b | US$31.89 | PS2.9x | E29.7% | 5.9% | Pharmaceuticals & Biotech | ||
ISRG | US$380.37 | 2.3% | 25.7% | US$137.9b | US$420.38 | PE67.9x | E11.6% | n/a | Healthcare | ||
SYK | US$329.28 | 0.4% | 15.3% | US$126.5b | US$372.35 | PE37.3x | E10.5% | 1.0% | Healthcare | ||
ELV | US$533.35 | 1.6% | 16.1% | US$124.6b | US$603.31 | PE19.9x | E12.3% | 1.2% | Healthcare | ||
MDT | US$81.55 | 0.8% | -8.8% | US$108.7b | US$94.77 | PE25.8x | E9.7% | 3.4% | Healthcare | ||
BSX | US$72.72 | 0.7% | 36.6% | US$108.0b | US$81.17 | PE60.6x | E18.1% | n/a | Healthcare | ||
REGN | US$955.76 | 5.8% | 27.5% | US$106.9b | US$1,034.47 | PE27.3x | E12.2% | n/a | Pharmaceuticals & Biotech | ||
VRTX | US$418.82 | 4.1% | 19.6% | US$105.9b | US$462.09 | PE26.9x | E10.2% | n/a | Pharmaceuticals & Biotech | ||
CI | US$347.35 | -2.8% | 31.8% | US$98.5b | US$391.82 | PE27.3x | E17.8% | 1.6% | Healthcare | ||
GSK | UK£17.61 | 3.3% | 22.6% | UK£71.8b | UK£20.21 | PE16x | E11.9% | 3.3% | Pharmaceuticals & Biotech | ||
BMY | US$43.67 | -1.2% | -36.2% | US$89.3b | US$53.19 | PS1.9x | E43.8% | 5.5% | Pharmaceuticals & Biotech | ||
CSL | AU$279.90 | 2.0% | -7.7% | AU$135.3b | AU$303.85 | PE35.9x | E14.7% | 1.3% | Pharmaceuticals & Biotech | ||
HCA | US$309.42 | -0.006% | 11.1% | US$82.4b | US$344.35 | PE14.8x | E6.0% | 0.9% | Healthcare | ||
GILD | US$64.92 | -0.9% | -16.9% | US$81.6b | US$82.93 | PE166.9x | E36.5% | 4.7% | Pharmaceuticals & Biotech |